Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blue Cross Michigan backs Prilosec OTC

This article was originally published in The Tan Sheet

Executive Summary

Coupons offering $5 off the price of Prilosec OTC are now being mailed to 12,000 health plan members who could benefit from a discount on heartburn medication, Blue Cross Blue Shield of Michigan announces March 18. The cost of the coupon - which expires May 31, 2004 - is covered by the manufacturer, according to BCBSM. Similar discount programs supporting OTC use of Prilosec were undertaken in Fall 2003 by Blue Cross Blue Shield of Georgia and California (1"The Tan Sheet" Oct. 27, 2003, In Brief and 2"The Tan Sheet" Aug. 25, 2003, p. 6)...

You may also be interested in...



Blue Cross Georgia Prilosec OTC coupons

Wellpoint Health Networks expands coupon offerings for Prilosec OTC to its Blue Cross and Blue Shield Georgia members through a new coupon program, insurance provider announces Oct. 20. More than 25,000 insured members who have received proton pump inhibitor prescriptions will be sent information on the program, along with three Prilosec OTC coupons. Discounts include one free sample box of 14 pills and two $10 redemption coupons towards purchase of 28- or 42-count boxes. Coupons will reduce the cost of a one-month supply from $0.78 per tablet to $0.43 per tablet, BCBSGA estimates. Wellpoint has offered coupons for the drug through its California Blue Cross operating subsidiary as well (1"The Tan Sheet" Aug. 25, 2003, p. 6)...

Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices

Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole

Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics

FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel